Botanicure's Botanical Drug BOTA-NS1 Shows Early Promise for Cognitive Decline in Pilot Study
核心洞察
Botanicure (搜索) presented early clinical findings on its botanical drug candidate BOTA-NS1 (搜索) at the BIO International Convention, targeting individuals at the earliest stages of cognitive decline.
The single-arm, open-label pilot study enrolled 300 participants with subjective cognitive impairment (搜索) across four medical centers in Taiwan, with interim data from 53 completers showing significant improvements in global function and sleep disturbances.
Biomarker analyses indicated reductions in neuroinflammatory indicators, leading researchers to suggest BOTA-NS1 (搜索) may possess anti-neuroinflammatory properties.
Botanicure (搜索), a biotechnology company focused on developing novel therapeutics for neurological and aging-related diseases, presented its latest clinical findings at the BIO International Convention in the United States. The presentation, entitled "The Effect of Soy Extracts on Brain Health and Quality of Life in the Middle-Aged and Elderly Populations: A Pilot Study," highlighted early data on the company's botanical drug candidate BOTA-NS1 (搜索) for individuals at the earliest stages of cognitive decline.
Speaking on behalf of the research team, Dr. Chaur-Jong Hu, Dean of the College of Medicine at Taipei Medical University, noted that current dementia (搜索) treatment strategies are moving toward "the earlier, the better." He underscored the growing attention surrounding Botanicure (搜索)'s clinical findings on a botanical drug candidate targeting individuals at the earliest stages of cognitive decline.
Study Design and Patient Population
The pilot study was led by Dr. Hu and conducted across four major medical centers in Taiwan, including Taipei Medical University Hospital, Wan Fang Hospital, Shuang Ho Hospital, and Tri-Service General Hospital. The study enrolled 300 participants diagnosed by physicians as having subjective cognitive impairment (搜索) and employed a single-arm, open-label clinical design.
Dr. Hu explained that the study integrated clinical symptom assessment with blood-based biomarker analysis to evaluate participants with early cognitive concerns or subjective symptoms. In addition to observing changes in cognitive function, sleep quality, perceived pressure, and functions of life following treatment, the research team also analyzed relevant biomarkers to better understand the product's potential effects on brain health and neuroinflammatory responses.
Interim Findings
According to the study findings, BOTA-NS1 (搜索) demonstrated positive effects on global function, perceived pressure, and sleep disturbances. Dr. Hu noted that biomarker analyses showed reductions in neuroinflammatory indicators, leading the research team to believe that the product may possess anti-neuroinflammatory properties.
As of February this year, 53 participants had completed the study and their datasets had been collected from the 300 enrolled participants. Based on interim analysis results, BOTA-NS1 (搜索) showed significant improvements in global function and sleep disturbances following administration of the botanical gel product.
The Growing Dementia Burden in Taiwan
Dr. Hu stated that government-led epidemiological surveys estimate Taiwan's dementia (搜索) population at approximately 350,000 individuals. Among them, nearly half are classified as having mild or very mild cognitive impairment, representing an estimated 160,000 to 170,000 people living in the community.
Regarding the rapid growth of Taiwan's dementia (搜索) population, Dr. Hu explained that multiple factors are contributing to the trend, chief among them the country's rapidly aging population. Taiwan has already become a super-aged society, with individuals aged 65 and older accounting for more than 20% of the total population. As the elderly population expands, the prevalence of dementia and related disorders is expected to continue increasing, with rising risks associated with vascular diseases also playing an important role.
Clinical Context and Early Intervention
Dr. Hu emphasized that current therapeutic approaches and drug development efforts are increasingly focused on earlier intervention. The Botanicure (搜索) study targeted individuals with early warning signs or subjective cognitive complaints who had not yet progressed to clinically diagnosed dementia (搜索).
Distinguishing normal aging from dementia (搜索) is often challenging. Dr. Hu noted that physicians typically have limited consultation time, making information provided by family members particularly valuable. If cognitive decline is rapid, pronounced, or begins to interfere with daily functioning, medical evaluation should be sought promptly. Clinical practice today places strong emphasis on identifying mild and even very mild cases at the earliest possible stage.
He also pointed out that hospitals frequently manage behavioral and psychological symptoms of dementia (搜索), including delusions, hallucinations, and sleep disturbances. Many dementia patients experience disruptions in their sleep-wake cycle and present more severe symptoms at night, commonly referred to as "sundowning," characterized by daytime drowsiness and increased alertness at night. In addition to pharmacological treatments, non-pharmacological interventions remain an important component of patient care.
Shifting R&D Landscape
Reflecting on his observations at the BIO International Convention, Dr. Hu noted that venture capital and industry discussions on the future of Alzheimer's disease (搜索) are no longer focused solely on amyloid clearance. Increasing attention is being paid to brain metabolism impairment, neuroinflammation, combination therapies, and biomarker-driven approaches. These trends closely align with Botanicure (搜索)'s research and development strategy and provide valuable insights for future innovation.
Through its participation at BIO, Botanicure (搜索) aims not only to showcase the clinical progress of its botanical drug development program but also to foster deeper scientific exchange and technological collaboration with the global biopharmaceutical community.